Method of Using Cannabinoids Encapsulated in Phospholipid Carriers for Transmucosal and Transdermal Administration
A method of administering a composition having Cannabis sativa -derived substances nano-encapsulated in phospholipid vesicles for transmucosal and transdermal delivery is disclosed. A Cannabis sativa -derived formulation for transmucosal and transdermal delivery comprising Cannabis sativa -derived compounds nanoencapsulated in phospholipid-based vesicles is also disclosed. Cannabis sativa -derived extracts have enhanced bioavailability when encapsulated in nanosized phospholipid vesicles prior to administration to a subject as compared to non-encapsulated cannabinoids. A method of encapsulating cannabis -derived compounds in nanosized phospholipid vesicles is also disclosed
1 . A method for administration of a Cannabis sativa -derived substance in a transmucosal and/or transdermal delivery protocol comprising the steps of:
providing a preparation having one or more Cannabis sativa -derived substance nanoencapsulated in one or more phospholipid vesicles having phospholipids, ethanol, and water, said a Cannabis sativa -derived substance having a concentration of 0.01% to 1.0% w/w; and
administering a quantity of the preparation having 1 mg to 100 mg of Cannabis sativa -derived substance to an oral mucosa or an epidermis of a subject in need of treatment.
2 . The method of claim 1 , wherein the Cannabis sativa -derived substance is selected from cannabidiol (CBD), tetrahydrocannabinol (THC), Cannabis sativa -derived terpenes, Cannabis sativa -derived flavonoids, a whole plant extract of Cannabis sativa , and combinations thereof.
3 . The method of claim 2 , wherein the Cannabis sativa -derived substance is cannabidiol (CBD), tetrahydrocannabinol (THC), or a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC).
4 . The method of claim 1 , wherein the preparation is applied to the oral mucosa of the subject.
5 . The method of claim 4 , wherein the preparation of nanosized phospholipid vesicles is kept in contact with the oral mucosa for 1 minute to 10 minutes.
6 . The method of claim 1 , wherein the preparation is applied to an area of the epidermis of the subject.
7 . The method of claim 6 , wherein the preparation of nanosized phospholipid vesicles is kept in contact with the area of the epidermis for 1 minute to 24 hours.
8 . The method of claim 1 , wherein the nanosized phospholipid-based vesicles are sized from 25 nm to 200 nm.
9 . A method for intraoral transmucosal administration of a Cannabis sativa -derived substance comprising the steps of:
providing a preparation having one or more Cannabis sativa -derived substance selected from cannabidiol (CBD), tetrahydrocannabinol (THC), Cannabis sativa -derived terpenes, Cannabis sativa -derived flavonoids, a whole plant extract of Cannabis sativa , and combinations thereof, nanoencapsulated in one or more phospholipid vesicles, said one or more phospholipid vesicle having phospholipids, ethanol and water;
applying a quantity of the preparation having from 1 mg to 100 mg to the subject's oral mucosa; and
allowing the preparation to remain in contact with the oral mucosa for a period of time ranging from 1 minute to 10 minutes.
10 . The method of claim 9 , wherein the preparation of nanosized phospholipid vesicles has a Cannabis sativa -derived substance concentration of 0.01% to 1.0% w/w.
11 . The method of claim 9 , wherein the preparation of nanosized phospholipid vesicles is applied to the oral mucosa as a liquid drop, liquid spray, aerosol, liquid shot, gel, paste, lozenge, gum, gummy candy, hard candy, orally dissolving strip, tablet, or swish and swallow preparation.
12 . The method of claim 9 , wherein the preparation of nanosized phospholipid vesicles is kept in contact with the oral mucosa for 1 minute to 5 minutes.
13 . The method of claim 9 , wherein said oral mucosa is a sublingual mucosa, a buccal mucosa or an oral cavity mucosa.
14 . The method of claim 9 , wherein the phospholipid vesicles with nanoencapsulated Cannabis sativa -derived substance are sized from 25 nm to 200 nm.
15 . The method of claim 9 , wherein phosphatidylcholine (PC) is at least 50% of the phospholipid total in the phospholipid vesicles.
16 . A method for transdermal administration of a Cannabis sativa -derived substance comprising the steps of:
providing a preparation of a Cannabis sativa -derived substance, nanoencapsulated in one or more phospholipid vesicle having phospholipids, ethanol and water, said nanosized phospholipid-based vesicles being sized from 25 nm to 200 nm;
applying a quantity of the preparation having from 1 mg to 100 mg to an area of the subject's epidermis; and
allowing the preparation to remain in contact the epidermis for a period of time ranging from 1 minute to 24 hours.
17 . The method of claim 16 , wherein the Cannabis sativa -derived substance is selected from cannabidiol (CBD), tetrahydrocannabinol (THC), Cannabis sativa -derived terpenes, Cannabis sativa -derived flavonoids, a whole plant extract of Cannabis sativa , and combinations thereof.
18 . The method of claim 17 , wherein the Cannabis sativa -derived substance is cannabidiol (CBD), tetrahydrocannabinol (THC), or a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC).
19 . The method of claim 16 , wherein the preparation is applied to the epidermis in a cream, lotion, ointment, wax, topically applied spray, gel, or balm.
20 . The method of claim 16 , wherein the preparation is applied to the epidermis in a transdermal patch.